Abstract: The present disclosure relates to compounds of Formula (I) and (II): and pharmaceutically acceptable salts and isotopically labeled derivatives thereof, wherein X1, X2, R1, R2, R3, R4, R5, R6A, R6B and R7 are as defined herein, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.

Abstract: The present disclosure relates to compounds of Formula (I) and (II): and pharmaceutically acceptable salts and isotopically labeled derivatives thereof, wherein X1, X2, R1, R2, R3, R4, R5, R6, and R7 are as defined herein, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.

Abstract: The present disclosure relates to compounds of Formula (I) and (II): and pharmaceutically acceptable salts and/or isotopically labeled derivatives thereof, wherein X1, X2, RA, y, R3, R4, R5, R6, R7, a and b are as defined herein, and Ring A2 is a 6-membered heteroaryl ring, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.

Abstract: The present disclosure relates to compounds of Formula (I), (II), and (III): and pharmaceutically acceptable salts, tautomers, and/or isotopically labeled derivatives thereof, wherein X1, X2, RA, y, R3, R4, R5, R6, R7, R6A, R6B, a and b are as defined herein, and Ring A2 is a monocyclic pyrazolyl ring, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I) or (III). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.

Abstract: The present disclosure relates to compounds of Formula (I) and (II): and pharmaceutically acceptable salts, tautomers, and/or isotopically labeled derivatives thereof, wherein X1, X2, RA, y, R3, R4, R5, R6, R7, a and b are as defined herein, and Ring A2 is a 5-membered heteroaryl ring, provided the heteroaryl ring is not pyrazolyl, and methods of preparation of same. The present disclosure further relates to pharmaceutical compositions and methods of treatment, e.g., of cGAS-related diseases and disorders, comprising compounds of Formula (I). Compounds of Formula (II) may be useful as tool compounds in binding, functional, and/or cellular assays.

Abstract: The present disclosure relates to compounds of Formula (I-B): and pharmaceutically acceptable salts and tautomers thereof, wherein Ring A, Ring B, R1, R2a, R2b, R3, R4, m, n, and p are described herein, and methods of preparation, methods of treatment and prevention, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I-B), and pharmaceutically acceptable salts and tautomers thereof, in the treatment or prevention of NLRP3-related diseases and disorders.

Abstract: The present disclosure relates to compounds of Formula (I-A): and pharmaceutically acceptable salts and tautomers thereof, wherein Ring A, Ring B, R1, R2a, R2b, R3, m, n, and p are described herein, and methods of preparation, methods of treatment and prevention, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I-A), and pharmaceutically acceptable salts and tautomers thereof, in the treatment and prevention of NLRP3-related diseases and disorders.

Abstract: The present disclosure relates to compound of Formula (I), such as compounds of Formula (II), (III), and (IV), useful for cGAS modulation, wherein L1, R1, R2, R9, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, Y, and r are described therein.

Abstract: The present disclosure relates to compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, stereoisomer, tautomer, isotopic derivative, prodrug or polymorph thereof. Further provided are pharmaceutical compositions comprising the same, methods of preparation, and methods of use and treatment, e.g., as inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.

Abstract: The present disclosure relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A, R1, R2, R3, R4, and m are described herein, methods of preparation, methods of treatment, and pharmaceutical compositions comprising same. The present disclosure further relates to the use of the compounds of Formula (I), and pharmaceutically acceptable salts thereof, in the treatment of cGAS-related diseases and disorders.

Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R—R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein m, n, p, q A, B, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.